News tagged with pioglitazone
Pioglitazone
Pioglitazone is a prescription drug of the class thiazolidinedione (TZD) with hypoglycemic (antihyperglycemic, antidiabetic) action. Pioglitazone is marketed as trademarks Actos in the USA, Canada, the UK and Germany, Glustin in Europe,"Glizone" and "Pioz" in India by Zydus CND and USV respectively and Zactos in Mexico by Takeda Pharmaceuticals. Actos was the tenth-best selling drug in the U.S. in 2008, with sales exceeding $2.4 billion. Its cardiovascular safety profile compares favorably with rosiglitazone (Avandia), which was withdrawn after concerns about an increased risk of cardiac events, but pioglitazone has subsequently been found to be associated with bladder tumors and has been withdrawn in some countries.
This text uses material from Wikipedia and is available under the GNU Free Documentation License.
FDA approves 3 new drugs for type 2 diabetes
(HealthDay)—The U.S. Food and Drug Administration late Friday approved three new medications to help people battle type 2 diabetes.
Medications
Jan 26, 2013 |
5 / 5 (2) |
1
Thiazolidinedione use in patients with Type 2 diabetes may increase risk for diabetic macular edema
Treatment with glucose-lowering thiazolidinedione drugs in patients with Type 2 diabetes appears to be associated with an increased risk of diabetic macular edema (a complication that may affect vision) at 1-year and 10-year ...
Diabetes
Jun 11, 2012 |
not rated yet |
0
Diabetes drug linked to increased risk of bladder cancer
a drug used to treat type 2 diabetes - is associated with an increased risk of bladder cancer, finds a study published on BMJ today.
Cancer
May 31, 2012 |
not rated yet |
0
Thiazolidinediones tied to lower cancer risk in diabetes patients
(HealthDay) -- Thiazolidinediones are associated with a lower risk of liver and colorectal cancer in patients with type 2 diabetes, according to a study published in the May issue of Hepatology.
Cancer
Apr 27, 2012 |
not rated yet |
0
Medical societies respond to the FDA's safety announcement on the use of Actos
Diabetes leaders today are responding to the announcement made by the U.S. Food and Drug Administration (FDA) yesterday that the use of the diabetes medication Actos (pioglitazone) for more than one year may be associated ...
Medications
Jun 16, 2011 |
not rated yet |
0
